EA
BHVN

Emerald Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Emerald Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-171,023
Closed -$24.9M – 264
2022
Q2 		$24.9M Sell
171,023
-145,363
-46% -$18.6M 1.28% 23
2022
Q1 		$37.5M Buy
316,386
+59,686
+23% +$7.44M 1.43% 16
2021
Q4 		$35.4M Buy
256,700
+49,694
+24% +$6.32M 1.31% 23
2021
Q3 		$28.8M Buy
+207,006
New +$25.8M 1.04% 31
2021
Q1 		– Sell
-81,616
Closed -$7M – 317
2020
Q4 		$7M Sell
81,616
-116,836
-59% -$9.9M 0.23% 115
2020
Q3 		$12.9M Sell
198,452
-297,267
-60% -$19.5M 0.53% 74
2020
Q2 		$36.2M Sell
495,719
-84,960
-15% -$4.52M 1.58% 10
2020
Q1 		$19.8M Buy
580,679
+99,185
+21% +$4.54M 1.14% 27
2019
Q4 		$26.2M Buy
481,494
+164,848
+52% +$8.16M 1.11% 26
2019
Q3 		$13.2M Sell
316,646
-21,004
-6% -$887K 0.62% 64
2019
Q2 		$14.8M Sell
337,650
-255,143
-43% -$14.4M 0.59% 72
2019
Q1 		$30.5M Buy
592,793
+22,625
+4% +$977K 1.24% 23
2018
Q4 		$21.1M Sell
570,168
-10,245
-2% -$369K 1.04% 35
2018
Q3 		$21.8M Buy
580,413
+175,049
+43% +$6.44M 0.8% 44
2018
Q2 		$16M Buy
405,364
+42,115
+12% +$1.34M 0.6% 82
2018
Q1 		$9.36M Sell
363,249
-6,533
-2% -$195K 0.38% 106
2017
Q4 		$9.98M Buy
369,782
+126,455
+52% +$3.48M 0.38% 102
2017
Q3 		$9.1M Sell
243,327
-254,553
-51% -$7.72M 0.37% 101
2017
Q2 		$12.4M Buy
+497,880
New +$11.5M 0.52% 79

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Emerald Advisers's BHVN Position: Q3 2022 in Review

Emerald Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 171,023 shares — an estimated $24.9M sold.

Emerald Advisers first reported a position in BHVN in Q2 2017 and held it in 19 quarters. The position peaked at $37.5M in Q1 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Emerald Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Emerald Advisers sold 171,023 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $24.9M.
  • Emerald Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 19 quarters.
  • Emerald Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $37.5M in Q1 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Emerald Advisers's 13F filing for Q3 2022, filed 25 Oct 2022.